Ivermectin and mebendazole, 84% benefit in cancer

Overview

A presenter discusses a newly reported (not yet fully peer-reviewed) paper claiming strong real-world clinical outcomes when the antiparasitic drugs ivermectin and mebendazole are used together for a wide range of cancers.

Main claims and findings from the reported study

• Study design: A prospective observational cohort (not a randomized controlled trial).
• Clinical benefit ratio: The presenter states that 84.4% of patients achieved a “good outcome,” defined as either:
  • complete response (no evidence of disease),
  • partial response / regression, or
  • stable disease.
• Reported outcomes at follow-up (~6 months):
  • 32.8%: no evidence of disease
  • 15.6%: disease regression
  • 36.1%: stable disease
  • 15.6%: progression
• Cohort size:
  • 197 cancer patients at baseline
  • 122 completed follow-up
• Cancer diversity: The cancer types were heterogeneous, with examples including prostate, breast, lung, colon, and liver, plus “many others,” using a similar adjunct protocol across groups.

Treatment protocol and tolerability (as described)

• Regimen: Presented as off-label and using compounded capsules for 90 days:
  • ivermectin 25 mg daily
  • mebendazole 250 mg daily
• Adherence: About 87% reportedly adhered closely and took the full course.
• Side effects: Reported as mild, mostly gastrointestinal; most patients continued therapy:
  • 94% reported being able to carry on, with some dose adjustments.
• Concurrent treatments: Some patients were also receiving chemotherapy, radiotherapy, surgery, and dietary/supplement measures.

Analysis and interpretation offered in the video

• The presenter characterizes the results as “remarkable,” noting cancer’s typical progressive nature.
• The study is reported to have found no significant dose-response relationship (lower doses appearing similarly effective to higher doses within the dataset).
• The presenter repeatedly frames the evidence as hypothesis-generating, emphasizing key limitations:
  • observational (non-randomized) design
  • self-reported outcomes
  • possible selection bias
  • potential uncontrolled confounding
• Despite these caveats, the presenter claims a “compelling clinical signal,” suggesting repurposed drugs might help across multiple cancers and calling for large randomized, double-blind trials.

Drug rationale emphasized by the presenter

• Ivermectin: Described as acting through many anti-cancer pathways, such as:
  • reducing proliferation
  • reducing metastasis likelihood
  • affecting angiogenesis
  • impacting mitochondrial function
• Mebendazole: Described as targeting:
  • cancer stem cells
  • microtubules, leading to cell-cycle arrest
  • possible apoptosis and additional anti-tumor effects
• Synergy argument: The presenter suggests the drugs may have non-overlapping pathways, potentially enabling synergistic tumor regression and reducing resistance risk.

Financial and policy critique

• The presenter claims typical chemotherapy costs about $111,000 per year per patient, contrasted with what the paper frames as the drugs’ low cost (around $1,000–$2/year).
• They suggest the barrier to large trials may be less about definitive lack of promise and more about:
  • pharmaceutical incentives
  • lack of commercial motivation
• The video expresses frustration that governments and independent institutions are not funding or conducting the proposed trials.

Presenters or contributors

• Nick Hushler — lead author of the referenced paper (described as a friend of the channel)
• Video presenter/channel host — unnamed in the subtitles